# Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

> **NCT00309062** · PHASE3 · COMPLETED · sponsor: **Allergopharma GmbH & Co. KG**

## Conditions studied

- Birch Pollen Allergy

## Interventions

- **BIOLOGICAL:** Recombinant birch pollen

## Key facts

- **NCT ID:** NCT00309062
- **Lead sponsor:** Allergopharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2006-06
- **Final completion:** 2009-06
- **Target enrollment:** — (—)
- **Last updated:** 2013-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00309062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00309062, "Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00309062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*